Related Experiment Video
Updated: Jul 18, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
Published on: March 30, 2019
Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b
Gary K Scott1, Andrei Goga, Dipa Bhaumik
1Buck Institute for Age Research, Novato, California 94945, USA.
Abstract:
Deregulation of micro-RNAs (miRNAs) is emerging as a major aspect of cancer etiology because their capacity to direct the translation and stability of targeted transcripts can dramatically influence cellular physiology. To explore the potential of exogenously applied miRNAs to suppress oncogenic proteins, the ERBB oncogene family was chosen with a bioinformatics search identifying targeting seed sequences for miR-125a and miR-125b within the 3'-untranslated regions of both ERBB2 and ERBB3. Using the human breast cancer cell line SKBR3 as a model for ERBB2 and ERBB3 dependence, infection of these cells with retroviral constructs expressing either miR-125a or miR-125b resulted in suppression of ERBB2 and ERBB3 at both the transcript and protein level. Luciferase constructs containing the 3' 3'-untranslated regions of ERBB2 and ERBB3 demonstrated approximately 35% less activity in miR-125a- and miR-125b-expressing cells relative to controls. Additionally, phosphorylation of ERK1/2 and AKT was suppressed in SKBR3 cells overexpressing either miR-125a or miR-125b. Consistent with suppression of both ERBB2 and ERBB3 signaling, miR-125a-or miR-125b-overexpressing SKBR3 cells were impaired in their anchorage-dependent growth and exhibited reduced migration and invasion capacities. Parallel studies performed on MCF10A cells demonstrated that miR-125a or miR-125b overexpression produced only marginal influences on the growth and migration of these non-transformed human mammary epithelial cells. These results illustrate the feasibility of using miRNAs as a therapeutic strategy to suppress oncogene expression and function.
Insights
MicroRNAs (miRNAs) can suppress cancer-driving genes like ERBB2 and ERBB3. Introducing miR-125a or miR-125b reduced tumor cell growth, migration, and invasion, showing therapeutic potential.
Area of Science:
- Molecular Biology
- Oncology
- Gene Regulation
Background:
- MicroRNA (miRNA) deregulation is implicated in cancer development.
- miRNAs regulate gene expression by targeting mRNA transcripts.
- The ERBB oncogene family plays a role in various cancers.
Purpose of the Study:
- To investigate the therapeutic potential of exogenously applied miRNAs to suppress oncogenic ERBB proteins.
- To identify specific miRNAs targeting ERBB2 and ERBB3.
Main Methods:
- Bioinformatic analysis to identify miRNA targeting sites in ERBB2 and ERBB3 3'-untranslated regions.
- Retroviral delivery of miR-125a and miR-125b into human breast cancer cells (SKBR3).
- Assessment of ERBB2 and ERBB3 transcript and protein levels, downstream signaling pathways (ERK1/2, AKT), and cellular functions (growth, migration, invasion).
Main Results:
- miR-125a and miR-125b successfully suppressed ERBB2 and ERBB3 at transcript and protein levels in SKBR3 cells.
- Luciferase assays confirmed direct targeting of ERBB2 and ERBB3 3'-UTRs by miR-125a/b.
- Overexpression of miR-125a/b inhibited ERK1/2 and AKT phosphorylation, impaired anchorage-dependent growth, and reduced migration and invasion.
- Non-cancerous MCF10A cells showed minimal effects from miR-125a/b overexpression.
Conclusions:
- Exogenous miR-125a and miR-125b can effectively suppress oncogenic ERBB2 and ERBB3 expression and function.
- This study demonstrates the feasibility of using miRNAs as a therapeutic strategy against ERBB-driven cancers.
- miRNA-based therapies offer a promising approach to target oncogene expression and cellular oncogenic phenotypes.
Related Concept Videos
MicroRNAs
MicroRNAs
Experimental RNAi
Abnormal Proliferation
Mitogens and the Cell Cycle
Negative Regulator Molecules